Gilenia Advisory Committee: Is REMS + Phase IV > FDA Safety Concerns?
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis' oral multiple sclerosis drug Gilenia (fingolimod) faces an unusually large briefing package from FDA focused on safety concerns.